Our Science – Onda Website
Masanori Onda, M.D., Ph.D.
New approach to Cancer Therapy: Recombinant Immunotoxins
Reducing the immunogenicity of the protein therapeutics
Reducing immunogenicity of PE38 based immunotoxins
Identification of human B lymphocyte epitopes
New Target for Mesothelioma and Gynecological Malignancies: Mesothelin
Soluble mesothelin is useful biomarker for mesothelioma
New antibody for mesothelin & MPF
Investigating new molecular target for immunotoxin (CAPC, PATE etc)
New Target for Osteosarcoma and neuroblastoma
New Target for lympoma
CD30 antibody which does not bind shedding epitopes
This page was last updated on 4/10/2014.